Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba.
More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.
Key Topics Covered:
EXECUTIVE SUMMARY
US
Insights and strategic recommendations
US payers are adopting a wait-and-see approach for biosimilar Basaglar
Bibliography
FIVE MAJOR EU MARKETS
Insights and strategic recommendations
Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to
reduce costs
Payers use biosimilars to pressure originators on pricing
Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
Patient switching requires significant discounts of at least 30%
Given attractive discounts, payers will use a variety of market access tools to drive Basaglar's uptake
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
First Quarter 2024
Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com.
The earnings release can be found at...
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...